Parrey A, Lakshman A, Ismail M, Ashraf M, et al. Upfront low-dose biosimilar rituximab as first biologic therapy after triple csDMARD failure in seropositive rheumatoid arthritis: a prospective real-world strategy study. Clin Rheumatol 2026 Jun 13. doi: 10.1007/s10067-026-08223.
PMID: 42287541